Stirring the pot: Can dietary modification alleviate the burden of CKD?

Nutrients

Volumn 9, Issue 3, 2017, Pages

  Snelson, Matthew ^a   Clarke, Rachel E ^a,b   Coughlan, Melinda T ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Advanced glycation end products; Albuminuria; Cardiovascular disease; Chronic kidney disease; Diabetes; Diet; Inflammation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; FRUCTOSE; OMEGA 3 FATTY ACID; ORGANOPHOSPHORUS COMPOUND; PARATHYROID HORMONE; PHOSPHATE; POTASSIUM; SODIUM; TRIACYLGLYCEROL; VITAMIN D;

ALBUMINURIA; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; COLON FLORA; DIABETES MELLITUS; DIETARY FIBER; DIETARY INTAKE; FERMENTATION; HEMODYNAMICS; HOMEOSTASIS; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; METABOLIC ACIDOSIS; MORTALITY; NONHUMAN; PROTEIN RESTRICTION; PROTEINURIA; REVIEW; SODIUM RESTRICTION; ADVERSE EFFECTS; ANIMAL; COST OF ILLNESS; DIET THERAPY; DIETARY SUPPLEMENT; DISEASE COURSE; EVIDENCE BASED MEDICINE; HEALTHY DIET; HEALTHY LIFESTYLE; KIDNEY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ANIMALS; COMBINED MODALITY THERAPY; COST OF ILLNESS; DIET, PROTEIN-RESTRICTED; DIET, SODIUM-RESTRICTED; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HEALTHY DIET; HEALTHY LIFESTYLE; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 85015236182     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9030265     Document Type: Review

References (240)

1. Levey, A.S.; Coresh, J. Chronic kidney disease. Lancet 2012, 379, 165–180. [CrossRef]
2. Levey, A.S.; de Jong, P.E.; Coresh, J.; El Nahas, M.; Astor, B.C.; Matsushita, K.; Gansevoort, R.T.; Kasiske, B.L.; Eckardt, K.-U. The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int. 2011, 80, 17–28. [CrossRef] [PubMed]
3. James, M.T.; Hemmelgarn, B.R.; Tonelli, M. Early recognition and prevention of chronic kidney disease. Lancet 2010, 375, 1296–1309. [CrossRef]
4. Weiner, D.E.; Tighiouart, H.; Amin, M.G.; Stark, P.C.; MacLeod, B.; Griffith, J.L.; Salem, D.N.; Levey, A.S.; Sarnak, M.J. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J. Am. Soc. Nephrol. 2004, 15, 1307–1315. [CrossRef] [PubMed]
5. Eckardt, K.-U.; Coresh, J.; Devuyst, O.; Johnson, R.J.; Köttgen, A.; Levey, A.S.; Levin, A. Evolving importance of kidney disease: From subspecialty to global health burden. Lancet 2013, 382, 158–169. [CrossRef]
6. Cordain, L.; Eaton, S.B.; Sebastian, A.; Mann, N.; Lindeberg, S.; Watkins, B.A.; O’Keefe, J.H.; Brand-Miller, J. Origins and evolution of the Western diet: Health implications for the 21st century. Am. J. Clin. Nutr. 2005, 81, 341–354. [PubMed]
7. Odermatt, A. The Western-style diet: A major risk factor for impaired kidney function and chronic kidney disease. Am. J. Physiol. Ren. Physiol. 2011, 301, F919–F931. [CrossRef] [PubMed]
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013, 3, 1–150.
9. Dunkler, D.; Kohl, M.; Teo, K.K.; Heinze, G.; Dehghan, M.; Clase, C.M.; Gao, P.; Yusuf, S.; Mann, J.F.; Oberbauer, R. Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. Nephrol. Dial. Transplant. 2015, 30, 76–85. [CrossRef] [PubMed]
10. Diamond, J.R. Effects of dietary interventions on glomerular pathophysiology. Am. J. Physiol. Ren. Physiol. 1990, 258, F1–F8.
11. Fouque, D.; Aparicio, M. Eleven reasons to control the protein intake of patients with chronic kidney disease. Nat. Clin. Pract. Nephrol. 2007, 3, 383–392. [CrossRef] [PubMed]
12. Kaysen, G.A.; Gambertoglio, J.; Jimenez, I.; Jones, H.; Hutchison, F.N. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int. 1986, 29, 572–577. [CrossRef] [PubMed]
13. Edwards, C.A.; Parrett, A.; Khanna, S. Nondigestible Carbohydrates. In Carbohydrates in Food, 2nd ed.; CRC Press: Boca Raton, FL, USA, 2006; pp. 273–303.
14. Ash, S.; Campbell, K.L.; Bogard, J.; Millichamp, A. Nutrition prescription to achieve positive outcomes in chronic kidney disease: A systematic review. Nutrients 2014, 6, 416–451. [CrossRef] [PubMed]
15. Bellizzi, V.; Di Iorio, B.R.; De Nicola, L.; Minutolo, R.; Zamboli, P.; Trucillo, P.; Catapano, F.; Cristofano, C.; Scalfi, L.; Conte, G.; on behalf of the ES-g. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int. 2007, 71, 245–251. [CrossRef] [PubMed]
16. Di Iorio, B.R.; Bellizzi, V.; Bellasi, A.; Torraca, S.; D’Arrigo, G.; Tripepi, G.; Zoccali, C. Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. Nephrol. Dial. Transplant. 2013, 28, 632–640. [CrossRef] [PubMed]
17. Schwingshackl, L.; Hoffmann, G. Comparison of high vs. normal/low protein diets on renal function in subjects without chronic kidney disease: A systematic review and meta-analysis. PLoS ONE 2014, 9, e97656. [CrossRef] [PubMed]
18. Jarusiripipat, C.; Shapiro, J.I.; Chan, L.; Schrier, R.W. Reduction of remnant nephron hypermetabolism by protein restriction. Am. J. Kidney Dis. 1991, 18, 367–374. [CrossRef]
19. Kleinknecht, C.; Salusky, I.; Broyer, M.; Gubler, M.-C. Effect of various protein diets on growth, renal function, and survival of uremic rats. Kidney Int. 1979, 15, 534–541. [CrossRef] [PubMed]
20. Kenner, C.H.; Evan, A.P.; Blomgren, P.; Aronoff, G.R.; Luft, F.C. Effect of protein intake on renal function and structure in partially nephrectomized rats. Kidney Int. 1985, 27, 739–750. [CrossRef] [PubMed]
21. Hostetter, T.H.; Meyer, T.W.; Rennke, H.G.; Brenner, B.M.; Noddin, J.A.; Sandstrom, D.J. Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int. 1986, 30, 509–517. [CrossRef] [PubMed]
22. Robertson, L.M.; Waugh, N.; Robertson, A. Protein restriction for diabetic renal disease. Cochrane Libr. 2007, 4, CD002181.
23. Williams, P.; Stevens, M.; Fass, G.; Irons, L.; Bone, J. Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: A prospective, randomized, controlled trial. QJM 1991, 81, 837–855. [CrossRef] [PubMed]
24. Klahr, S.; Levey, A.S.; Beck, G.J.; Caggiula, A.W.; Hunsicker, L.; Kusek, J.W.; Striker, G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N. Engl. J. Med. 1994, 330, 877–884. [CrossRef] [PubMed]
25. Carrero, J.J.; Stenvinkel, P.; Cuppari, L.; Ikizler, T.A.; Kalantar-Zadeh, K.; Kaysen, G.; Mitch, W.E.; Price, S.R.; Wanner, C.; Wang, A.Y.M.; et al. Etiology of the Protein-Energy Wasting Syndrome in Chronic Kidney Disease: A Consensus Statement From the International Society of Renal Nutrition and Metabolism (ISRNM). J. Ren. Nutr. 2013, 23, 77–90. [CrossRef] [PubMed]
26. Menon, V.; Kopple, J.D.; Wang, X.; Beck, G.J.; Collins, A.J.; Kusek, J.W.; Greene, T.; Levey, A.S.; Sarnak, M.J. Effect of a very low-protein diet on outcomes: Long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am. J. Kidney Dis. 2009, 53, 208–217. [CrossRef] [PubMed]
27. Dobre, M.; Yang, W.; Chen, J.; Drawz, P.; Hamm, L.L.; Horwitz, E.; Hostetter, T.; Jaar, B.; Lora, C.M.; Nessel, L.; et al. Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am. J. Kidney Dis. 2013, 62, 670–678. [CrossRef] [PubMed]
28. Shah, S.N.; Abramowitz, M.; Hostetter, T.H.; Melamed, M.L. Serum Bicarbonate Levels and the Progression of Kidney Disease: A Cohort Study. Am. J. Kidney Dis. 2009, 54, 270–277. [CrossRef] [PubMed]
29. Kovesdy, C.P.; Anderson, J.E.; Kalantar-Zadeh, K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol. Dial. Transplant. 2009, 24, 1232–1237. [CrossRef] [PubMed]
30. Adeva, M.M.; Souto, G. Diet-induced metabolic acidosis. Clin. Nutr. 2011, 30, 416–421. [CrossRef] [PubMed]
31. Alpern, R.J.; Sakhaee, K. The clinical spectrum of chronic metabolic acidosis: Homeostatic mechanisms produce significant morbidity. Am. J. Kidney Dis. 1997, 29, 291–302. [CrossRef]
32. Kurtz, I. Role of Ammonia in the Induction of Renal Hypertrophy. Am. J. Kidney Dis. 1991, 17, 650–653. [CrossRef]
33. Mitch, W.E.; Medina, R.; Grieber, S.; May, R.C.; England, B.K.; Price, S.R.; Bailey, J.L.; Goldberg, A.L. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J. Clin. Investig. 1994, 93, 2127–2133. [CrossRef] [PubMed]
34. Scialla, J.J.; Appel, L.J.; Wolf, M.; Yang, W.; Zhang, X.; Sozio, S.M.; Miller, E.R.; Bazzano, L.A.; Cuevas, M.; Glenn, M.J.; et al. Plant Protein Intake Is Associated with Fibroblast Growth Factor 23 and Serum Bicarbonate in Patients with CKD: The Chronic Renal Insufficiency Cohort Study. J. Ren. Nutr. 2012, 22, 379–388. [CrossRef] [PubMed]
35. Azadbakht, L.; Atabak, S.; Esmaillzadeh, A. Soy Protein Intake, Cardiorenal Indices, and C-Reactive Protein in Type 2 Diabetes With Nephropathy: A longitudinal randomized clinical trial. Diabetes Care 2008, 31, 648–654. [CrossRef] [PubMed]
36. Kontessis, P.; Jones, S.; Dodds, R.; Trevisan, R.; Nosadini, R.; Fioretto, P.; Borsato, M.; Sacerdoti, D.; Viberti, G. Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. Kidney Int. 1990, 38, 136–144. [CrossRef] [PubMed]
37. Garneata, L.; Stancu, A.; Dragomir, D.; Stefan, G.; Mircescu, G. Ketoanalogue-Supplemented Vegetarian Very Low–Protein Diet and CKD Progression. J. Am. Soc. Nephrol. 2016, 27, 2164–2176. [CrossRef] [PubMed]
38. Di Iorio, B.; Di Micco, L.; Marzocco, S.; De Simone, E.; De Blasio, A.; Sirico, M.; Nardone, L.; Group oboUS. Very Low-Protein Diet (VLPD) Reduces Metabolic Acidosis in Subjects with Chronic Kidney Disease: The “Nutritional Light Signal” of the Renal Acid Load. Nutrients 2017, 9, 69. [CrossRef] [PubMed]
39. Goraya, N.; Simoni, J.; Jo, C.-H.; Wesson, D.E. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int. 2014, 86, 1031–1038. [CrossRef] [PubMed]
40. Goraya, N.; Simoni, J.; Jo, C.-H.; Wesson, D.E. A Comparison of Treating Metabolic Acidosis in CKD Stage 4 Hypertensive Kidney Disease with Fruits and Vegetables or Sodium Bicarbonate. Clin. J. Am. Soc. Nephrol. 2013, 8, 371–381. [CrossRef] [PubMed]
41. Meijers, B.K.; Evenepoel, P. The gut–kidney axis: Indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol. Dial. Transplant. 2011, 26, 759–761. [CrossRef] [PubMed]
42. Niwa, T. Indoxyl sulfate is a nephro-vascular toxin. J. Ren. Nutr. 2010, 20, S2–S6. [CrossRef] [PubMed]
43. Tumur, Z.; Shimizu, H.; Enomoto, A.; Miyazaki, H.; Niwa, T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kB activation. Am. J. Nephrol. 2010, 31, 435–441. [CrossRef] [PubMed]
44. Bammens, B.; Evenepoel, P.; Keuleers, H.; Verbeke, K.; Vanrenterghem, Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006, 69, 1081–1087. [CrossRef] [PubMed]
45. Liabeuf, S.; Barreto, D.V.; Barreto, F.C.; Meert, N.; Glorieux, G.; Schepers, E.; Temmar, M.; Choukroun, G.; Vanholder, R.; Massy, Z.A. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol. Dial. Transplant. 2010, 25, 1183–1191. [CrossRef] [PubMed]
46. Patel, K.P.; Luo, F.J.-G.; Plummer, N.S.; Hostetter, T.H.; Meyer, T.W. The Production of p-Cresol Sulfate and Indoxyl Sulfate in Vegetarians versus Omnivores. Clin. J. Am. Soc. Nephrol. 2012, 7, 982–988. [CrossRef] [PubMed]
47. Kandouz, S.; Mohamed, A.S.; Zheng, Y.; Sandeman, S.; Davenport, A. Reduced protein bound uraemic toxins in vegetarian kidney failure patients treated by haemodiafiltration. Hemodial. Int. 2016, 20, 610–617. [CrossRef] [PubMed]
48. Koeth, R.A.; Wang, Z.; Levison, B.S.; Buffa, J.A.; Org, E.; Sheehy, B.T.; Britt, E.B.; Fu, X.; Wu, Y.; Li, L. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19, 576–585. [CrossRef] [PubMed]
49. Rampton, D.S.; Cohen, S.L.; Crammond, V.D.; Gibbons, J.; Lilburn, M.F.; Rabet, J.Y.; Vince, A.J.; Wager, J.D.; Wrong, O.M. Treatment of chronic renal failure with dietary fiber. Clin. Nephrol. 1984, 21, 159–163. [PubMed]
50. Vasilis, F.; Dimosthenis, V. Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes. Inflamm. Allergy-Drug Targets 2009, 8, 369–382.
51. Krishnamurthy, V.M.R.; Wei, G.; Baird, B.C.; Murtaugh, M.; Chonchol, M.B.; Raphael, K.L.; Greene, T.; Beddhu, S. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int. 2012, 81, 300–306. [CrossRef] [PubMed]
52. Evenepoel, P.; Meijers, B.K. Dietary fiber and protein: Nutritional therapy in chronic kidney disease and beyond. Kidney Int. 2012, 81, 227–229. [CrossRef] [PubMed]
53. Salmean, Y.A.; Segal, M.S.; Langkamp-Henken, B.; Canales, M.T.; Zello, G.A.; Dahl, W.J. Foods With Added Fiber Lower Serum Creatinine Levels in Patients With Chronic Kidney Disease. J. Ren. Nutr. 2013, 23, e29–e32. [CrossRef] [PubMed]
54. Salmean, Y.A.; Segal, M.S.; Palii, S.P.; Dahl, W.J. Fiber Supplementation Lowers Plasma p-Cresol in Chronic Kidney Disease Patients. J. Ren. Nutr. 2015, 25, 316–320. [CrossRef] [PubMed]
55. Bliss, D.Z.; Stein, T.P.; Schleifer, C.R.; Settle, R.G. Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. Am. J. Clin. Nutr. 1996, 63, 392–398. [PubMed]
56. Ali, A.A.; Ali, K.E.; Fadlalla, A.E.; Khalid, K.E. The effects of gum arabic oral treatment on the metabolic profile of chronic renal failure patients under regular haemodialysis in Central Sudan. Nat. Prod. Res. 2007, 22, 12–21. [CrossRef] [PubMed]
57. Chiavaroli, L.; Mirrahimi, A.; Sievenpiper, J.L.; Jenkins, D.J.A.; Darling, P.B. Dietary fiber effects in chronic kidney disease: A systematic review and meta-analysis of controlled feeding trials. Eur. J. Clin. Nutr. 2015, 69, 761–768. [CrossRef] [PubMed]
58. Meijers, B.K.I.; De Preter, V.; Verbeke, K.; Vanrenterghem, Y.; Evenepoel, P. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol. Dial. Transplant. 2010, 25, 219–224. [CrossRef] [PubMed]
59. Nakabayashi, I.; Nakamura, M.; Kawakami, K.; Ohta, T.; Kato, I.; Uchida, K.; Yoshida, M. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: A preliminary study. Nephrol. Dial. Transplant. 2011, 26, 1094–1098. [CrossRef] [PubMed]
60. Sirich, T.L.; Plummer, N.S.; Gardner, C.D.; Hostetter, T.H.; Meyer, T.W. Effect of Increasing Dietary Fiber on Plasma Levels of Colon-Derived Solutes in Hemodialysis Patients. Clin. J. Am. Soc. Nephrol. 2014, 9, 1603–1610. [CrossRef] [PubMed]
61. Johnson, D.W.; Atai, E.; Chan, M.; Phoon, R.K.S.; Scott, C.; Toussaint, N.D.; Turner, G.L.; Usherwood, T.; Wiggins, K.J. KHA-CARI Guideline: Early chronic kidney disease: Detection, prevention and management. Nephrology 2013, 18, 340–350. [CrossRef] [PubMed]
62. Cupisti, A.; D’Alessandro, C.; Valeri, A.; Capitanini, A.; Meola, M.; Betti, G.; Barsotti, G. Food Intake and Nutritional Status in Stable Hemodialysis Patients. Ren. Fail. 2010, 32, 47–54. [CrossRef] [PubMed]
63. Kalantar-Zadeh, K.; Kopple, J.D.; Deepak, S.; Block, D.; Block, G. Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J. Ren. Nutr. 2002, 12, 17–31. [CrossRef] [PubMed]
64. Khoueiry, G.; Waked, A.; Goldman, M.; El-Charabaty, E.; Dunne, E.; Smith, M.; Kleiner, M.; Lafferty, J.; Kalantar-Zadeh, K.; El-Sayegh, S. Dietary Intake in Hemodialysis Patients Does Not Reflect a Heart Healthy Diet. J. Ren. Nutr. 2011, 21, 438–447. [CrossRef] [PubMed]
65. Rossi, M.; Klein, K.; Johnson, D.W.; Campbell, K.L. Pre-, Pro-, and Synbiotics: Do They Have a Role in Reducing Uremic Toxins? A Systematic Review and Meta-Analysis. Int. J. Nephrol. 2012, 2012, 673631. [CrossRef] [PubMed]
66. Salmean, Y.A.; Zello, G.A.; Dahl, W.J. Foods with added fiber improve stool frequency in individuals with chronic kidney disease with no impact on appetite or overall quality of life. BMC Res. Notes 2013, 6, 510. [CrossRef] [PubMed]
67. Grabitske, H.A.; Slavin, J.L. Gastrointestinal Effects of Low-Digestible Carbohydrates. Crit. Rev. Food Sci. Nutr. 2009, 49, 327–360. [CrossRef] [PubMed]
68. Gansevoort, R.T.; Correa-Rotter, R.; Hemmelgarn, B.R.; Jafar, T.H.; Heerspink, H.J.L.; Mann, J.F.; Matsushita, K.; Wen, C.P. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2013, 382, 339–352. [CrossRef]
69. Hultström, M. Development of structural kidney damage in spontaneously hypertensive rats. J. Hypertens. 2012, 30, 1087–1091. [CrossRef] [PubMed]
70. Brenner, B.M.; Garcia, D.L.; Anderson, S. Glomeruli and blood pressure Less of one, more the other? Am. J. Hypertens. 1988, 1, 335–347. [CrossRef] [PubMed]
71. Jones-Burton, C.; Mishra, S.I.; Fink, J.C.; Brown, J.; Gossa, W.; Bakris, G.L.; Weir, M.R. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am. J. Nephrol. 2006, 26, 268–275. [CrossRef] [PubMed]
72. McMahon, E.J.; Bauer, J.D.; Hawley, C.M.; Isbel, N.M.; Stowasser, M.; Johnson, D.W.; Campbell, K.L. A randomized trial of dietary sodium restriction in CKD. J. Am. Soc. Nephrol. 2013, 24, 2096–2103. [CrossRef] [PubMed]
73. Slagman, M.C.J.; Waanders, F.; Hemmelder, M.H.; Woittiez, A.-J.; Janssen, W.M.T.; Lambers Heerspink, H.J.; Navis, G.; Laverman, G.D. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: Randomised controlled trial. BMJ 2011, 343, d4366. [CrossRef] [PubMed]
74. Adrogué, H.J.; Madias, N.E. Sodium and Potassium in the Pathogenesis of Hypertension. N. Engl. J. Med. 2007, 356, 1966–1978. [CrossRef] [PubMed]
75. Tyson, C.C.; Kuchibhatla, M.; Patel, U.D.; Pun, P.H.; Chang, A.; Nwankwo, C.; Joseph, M.A.; Svetkey, L.P. Impact of Kidney Function on Effects of the Dietary Approaches to Stop Hypertension (Dash) Diet. J. Hypertens. 2014, 3, 1000168.
76. Noori, N.; Kalantar-Zadeh, K.; Kovesdy, C.P.; Murali, S.B.; Bross, R.; Nissenson, A.R.; Kopple, J.D. Dietary potassium intake and mortality in long-term hemodialysis patients. Am. J. Kidney Dis. 2010, 56, 338–347. [CrossRef] [PubMed]
77. Cheng, J.; Zhang, W.; Zhang, X.; Li, X.; Chen, J. Efficacy and Safety of Paricalcitol Therapy for Chronic Kidney Disease: A Meta-Analysis. Clin. J. Am. Soc. Nephrol. 2012, 7, 391–400. [CrossRef] [PubMed]
78. Tomasello, S.P.B. Secondary Hyperparathyroidism and Chronic Kidney Disease. Diabetes Spectr. 2008, 21, 19–25. [CrossRef]
79. Saravanan, P.; Davidson, N.C. Risk Assessment for Sudden Cardiac Death in Dialysis Patients. Circ. Arrhythm. Electrophysiol. 2010, 3, 553–559. [CrossRef] [PubMed]
80. Drechsler, C.; Pilz, S.; Obermayer-Pietsch, B.; Verduijn, M.; Tomaschitz, A.; Krane, V.; Espe, K.; Dekker, F.; Brandenburg, V.; März, W.; et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur. Heart J. 2010, 31, 2253–2261. [CrossRef] [PubMed]
81. Pilz, S.; Iodice, S.; Zittermann, A.; Grant, W.B.; Gandini, S. Vitamin D Status and Mortality Risk in CKD: A Meta-analysis of Prospective Studies. Am. J. Kidney Dis. 2011, 58, 374–382. [CrossRef] [PubMed]
82. Goodman, W.G.; Goldin, J.; Kuizon, B.D.; Yoon, C.; Gales, B.; Sider, D.; Wang, Y.; Chung, J.; Emerick, A.; Greaser, L.; et al. Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis. N. Engl. J. Med. 2000, 342, 1478–1483. [CrossRef] [PubMed]
83. Block, G.A.; Hulbert-Shearon, T.E.; Levin, N.W.; Port, F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am. J. Kidney Dis. 1998, 31, 607–617. [CrossRef] [PubMed]
84. Keyzer, C.A.; Lambers-Heerspink, H.J.; Joosten, M.M.; Deetman, P.E.; Gansevoort, R.T.; Navis, G.; Kema, I.P.; de Zeeuw, D.; Bakker, S.J.; de Borst, M.H.; Group, P.S. Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake. Clin. J. Am. Soc. Nephrol. 2015, 10, 2119–2127. [CrossRef] [PubMed]
85. Xu, L.; Wan, X.; Huang, Z.; Zeng, F.; Wei, G.; Fang, D.; Deng, W.; Li, Y. Impact of Vitamin D on Chronic Kidney Diseases in Non-Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2013, 8, e61387. [CrossRef] [PubMed]
86. de Boer, I.H.; Sachs, M.; Hoofnagle, A.N.; Utzschneider, K.M.; Kahn, S.E.; Kestenbaum, B.; Himmelfarb, J. Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. Kidney Int. 2013, 83, 323–330. [CrossRef] [PubMed]
87. Fishbane, S.; Chittineni, H.; Packman, M.; Dutka, P.; Ali, N.; Durie, N. Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial. Am. J. Kidney Dis. 2009, 54, 647–652. [CrossRef] [PubMed]
88. de Zeeuw, D.; Agarwal, R.; Amdahl, M.; Audhya, P.; Coyne, D.; Garimella, T.; Parving, H.-H.; Pritchett, Y.; Remuzzi, G.; Ritz, E.; et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010, 376, 1543–1551. [CrossRef]
89. Alborzi, P.; Patel, N.A.; Peterson, C.; Bills, J.E.; Bekele, D.M.; Bunaye, Z.; Light, R.P.; Agarwal, R. Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial. Hypertension 2008, 52, 249–255. [CrossRef] [PubMed]
90. Kandula, P.; Dobre, M.; Schold, J.D.; Schreiber, M.J.; Mehrotra, R.; Navaneethan, S.D. Vitamin D Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials. Clin. J. Am. Soc. Nephrol. 2011, 6, 50–62. [CrossRef] [PubMed]
91. Han, T.; Rong, G.; Quan, D.; Shu, Y.; Liang, Z.; She, N.; Liu, M.; Yang, B.; Cheng, G.; Lv, Y.; et al. Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease. BioMed Res. Int. 2013, 2013, 320560. [CrossRef] [PubMed]
92. de Zeeuw, D.; Remuzzi, G.; Parving, H.-H.; Keane, W.F.; Zhang, Z.; Shahinfar, S.; Snapinn, S.; Cooper, M.E.; Mitch, W.E.; Brenner, B.M. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004, 65, 2309–2320. [CrossRef] [PubMed]
93. Agarwal, R.; Acharya, M.; Tian, J.; Hippensteel, R.L.; Melnick, J.Z.; Qiu, P.; Williams, L.; Batlle, D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005, 68, 2823–2828. [CrossRef] [PubMed]
94. de Borst, M.H.; Hajhosseiny, R.; Tamez, H.; Wenger, J.; Thadhani, R.; Goldsmith, D.J.A. Active Vitamin D Treatment for Reduction of Residual Proteinuria: A Systematic Review. J. Am. Soc. Nephrol. 2013, 24, 1863–1871. [CrossRef] [PubMed]
95. Ruggenenti, P.; Perna, A.; Gherardi, G.; Garini, G.; Zoccali, C.; Salvadori, M.; Scolari, F.; Schena, F.P.; Remuzzi, G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354, 359–364. [CrossRef]
96. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.-H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2001, 345, 861–869. [CrossRef] [PubMed]
97. Zheng, Z.; Shi, H.; Jia, J.; Li, D.; Lin, S. Vitamin D supplementation and mortality risk in chronic kidney disease: A meta-analysis of 20 observational studies. BMC Nephrol. 2013, 14, 199. [CrossRef] [PubMed]
98. Mann, M.C.; Hobbs, A.J.; Hemmelgarn, B.R.; Roberts, D.J.; Ahmed, S.B.; Rabi, D.M. Effect of oral vitamin D analogus on mortality and cardiovascular outcomes among adults with chronic kidney disease: A meta-analysis. Clin. Kidney J. 2015, 8, 41–48. [CrossRef] [PubMed]
99. Morrone, L.F.; Cozzolino, M. The beneficial impact of vitamin D treatment in CKD patients: What’s next? Clin. Kidney J. 2015, 8, 38–40. [CrossRef] [PubMed]
100. Theodoratou, E.; Tzoulaki, I.; Zgaga, L.; Ioannidis, J.P.A. Vitamin D and multiple health outcomes: Umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014, 348, g2035. [CrossRef] [PubMed]
101. Blaine, J.; Chonchol, M.; Levi, M. Renal Control of Calcium, Phosphate, and Magnesium Homeostasis. Clin. J. Am. Soc. Nephrol. 2015, 10, 1257–1272. [CrossRef] [PubMed]
102. Bover, J.; Andrés, E.; Lloret, M.J.; Aguilar, A.; Ballarín, J. Dietary and Pharmacological Control of Calcium and Phosphate Metabolism in Dialysis Patients. Blood Purif. 2009, 27, 369–386. [CrossRef] [PubMed]
103. Levin, A.; Bakris, G.L.; Molitch, M.; Smulders, M.; Tian, J.; Williams, L.A.; Andress, D.L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2006, 71, 31–38. [CrossRef] [PubMed]
104. Achinger, S.G.; Ayus, J.C. Left Ventricular Hypertrophy: Is Hyperphosphatemia among Dialysis Patients a Risk Factor? J. Am. Soc. Nephrol. 2006, 17, S255–S261. [CrossRef] [PubMed]
105. Hruska, K.A.; Saab, G.; Mathew, S.; Lund, R. Phosphorus Metabolism and Management in Chronic Kidney Disease: Renal Osteodystrophy, Phosphate Homeostasis, and Vascular Calcification. Semin. Dial. 2007, 20, 309–315. [CrossRef] [PubMed]
106. Voormolen, N.; Noordzij, M.; Grootendorst, D.C.; Beetz, I.; Sijpkens, Y.W.; van Manen, J.G.; Boeschoten, E.W.; Huisman, R.M.; Krediet, R.T.; Dekker, F.W.; group tPs. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol. Dial. Transplant. 2007, 22, 2909–2916. [CrossRef] [PubMed]
107. Kestenbaum, B.; Sampson, J.N.; Rudser, K.D.; Patterson, D.J.; Seliger, S.L.; Young, B.; Sherrard, D.J.; Andress, D.L. Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease. J. Am. Soc. Nephrol. 2005, 16, 520–528. [CrossRef] [PubMed]
108. Eddington, H.; Hoefield, R.; Sinha, S.; Chrysochou, C.; Lane, B.; Foley, R.N.; Hegarty, J.; New, J.; O’Donoghue, D.J.; Middleton, R.J.; et al. Serum Phosphate and Mortality in Patients with Chronic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2010, 5, 2251–2257. [CrossRef] [PubMed]
109. Block, G.A.; Klassen, P.S.; Lazarus, J.M.; Ofsthun, N.; Lowrie, E.G.; Chertow, G.M. Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. J. Am. Soc. Nephrol. 2004, 15, 2208–2218. [CrossRef] [PubMed]
110. Young, E.W.; Albert, J.M.; Satayathum, S.; Goodkin, D.A.; Pisoni, R.L.; Akiba, T.; Akizawa, T.; Kurokawa, K.; Bommer, J.; Piera, L.; et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005, 67, 1179–1187. [CrossRef] [PubMed]
111. Ganesh, S.K.; Stack, A.G.; Levin, N.W.; Hulbert-Shearon, T.E.; Port, F.K. Association of Elevated Serum PO4, Ca × PO4 Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients. J. Am. Soc. Nephrol. 2001, 12, 2131–2138. [PubMed]
112. Kovesdy, C.; Kalantar-Zadeh, K. Bone and mineral disorders in pre-dialysis CKD. Int. Urol. Nephrol. 2008, 40, 427–440. [CrossRef] [PubMed]
113. Schwarz, S.; Trivedi, B.K.; Kalantar-Zadeh, K.; Kovesdy, C.P. Association of Disorders in Mineral Metabolism with Progression of Chronic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2006, 1, 825–831. [CrossRef] [PubMed]
114. Zoccali, C.; Ruggenenti, P.; Perna, A.; Leonardis, D.; Tripepi, R.; Tripepi, G.; Mallamaci, F.; Remuzzi, G. Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. J. Am. Soc. Nephrol. 2011, 22, 1923–1930. [CrossRef] [PubMed]
115. Chue, C.D.; Edwards, N.C.; Davis, L.J.; Steeds, R.P.; Townend, J.N.; Ferro, C.J. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrol. Dial. Transplant. 2011, 26, 2576–2582. [CrossRef] [PubMed]
116. Sim, J.J.; Bhandari, S.K.; Smith, N.; Chung, J.; Liu, I.L.A.; Jacobsen, S.J.; Kalantar-Zadeh, K. Phosphorus and Risk of Renal Failure in Subjects with Normal Renal Function. Am. J. Med. 2013, 126, 311–318. [CrossRef] [PubMed]
117. Kalantar-Zadeh, K.; Gutekunst, L.; Mehrotra, R.; Kovesdy, C.P.; Bross, R.; Shinaberger, C.S.; Noori, N.; Hirschberg, R.; Benner, D.; Nissenson, A.R.; et al. Understanding Sources of Dietary Phosphorus in the Treatment of Patients with Chronic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2010, 5, 519–530. [CrossRef] [PubMed]
118. Kloppenburg, W.D.; Stegeman, C.A.; Kremer Hovinga, T.K.; Vastenburg, G.; Vos, P.; de Jong, P.E.; Huisman, R.M. Effect of prescribing a high protein diet and increasing the dose of dialysis on nutrition in stable chronic haemodialysis patients: A randomized, controlled trial. Nephrol. Dial. Transplant. 2004, 19, 1212–1223. [CrossRef] [PubMed]
119. Cupisti, A.; Kalantar-Zadeh, K. Management of Natural and Added Dietary Phosphorus Burden in Kidney Disease. Semin. Nephrol. 2013, 33, 180–190. [CrossRef] [PubMed]
120. Uribarri, J.; Calvo, M.S. Hidden Sources of Phosphorus in the Typical American Diet: Does it Matter in Nephrology? Semin. Dial. 2003, 16, 186–188. [CrossRef] [PubMed]
121. Calvo, M.S.; Moshfegh, A.J.; Tucker, K.L. Assessing the Health Impact of Phosphorus in the Food Supply: Issues and Considerations. Adv. Nutr. Int. Rev. J. 2014, 5, 104–113. [CrossRef] [PubMed]
122. Sinha, A.; Prasad, N. Dietary management of hyperphosphatemia in chronic kidney disease. Clin. Queries Nephrol. 2014, 3, 38–45. [CrossRef]
123. Nadkarni, G.N.; Uribarri, J. Phosphorus and the Kidney: What Is Known and What Is Needed. Adv. Nutr. Int. Rev. J. 2014, 5, 98–103. [CrossRef] [PubMed]
124. Takeda, E.; Yamamoto, H.; Yamanaka-Okumura, H.; Taketani, Y. Increasing Dietary Phosphorus Intake from Food Additives: Potential for Negative Impact on Bone Health. Adv. Nutr. Int. Rev. J. 2014, 5, 92–97. [CrossRef] [PubMed]
125. McCutcheon, J.; Campbell, K.; Ferguson, M.; Day, S.; Rossi, M. Prevalence of Phosphorus-Based Additives in the Australian Food Supply: A Challenge for Dietary Education? J. Ren. Nutr. 2015, 25, 440–444. [CrossRef] [PubMed]
126. Guida, B.; Piccoli, A.; Trio, R.; Laccetti, R.; Nastasi, A.; Paglione, A.; Memoli, A.; Memoli, B. Dietary phosphate restriction in dialysis patients: A new approach for the treatment of hyperphosphataemia. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 879–884. [CrossRef] [PubMed]
127. Sullivan, C.; Sayre, S.S.; Leon, J.B.; Machekano, R.; Love, T.E.; Porter, D.; Marbury, M.; Sehgal, A.R. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial. JAMA 2009, 301, 629–635. [CrossRef] [PubMed]
128. Shinaberger, C.S.; Greenland, S.; Kopple, J.D.; Van Wyck, D.; Mehrotra, R.; Kovesdy, C.P.; Kalantar-Zadeh, K. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am. J. Clin. Nutr. 2008, 88, 1511–1518. [CrossRef] [PubMed]
129. Lynch, K.E.; Lynch, R.; Curhan, G.C.; Brunelli, S.M. Prescribed Dietary Phosphate Restriction and Survival among Hemodialysis Patients. Clin. J. Am. Soc. Nephrol. 2011, 6, 620–629. [CrossRef] [PubMed]
130. Sherman, R.A. Dietary Phosphate Restriction and Protein Intake in Dialysis Patients: A Misdirected Focus. Semin. Dial. 2007, 20, 16–18. [CrossRef] [PubMed]
131. Benini, O.; D’Alessandro, C.; Gianfaldoni, D.; Cupisti, A. Extra-Phosphate Load from Food Additives in Commonly Eaten Foods: A Real and Insidious Danger for Renal Patients. J. Ren. Nutr. 2011, 21, 303–308. [CrossRef] [PubMed]
132. Sherman, R.A.; Mehta, O. Phosphorus and Potassium Content of Enhanced Meat and Poultry Products: Implications for Patients Who Receive Dialysis. Clin. J. Am. Soc. Nephrol. 2009, 4, 1370–1373. [CrossRef] [PubMed]
133. Zhao, L.G.; Sun, J.W.; Yang, Y.; Ma, X.; Wang, Y.Y.; Xiang, Y.B. Fish consumption and all-cause mortality: A meta-analysis of cohort studies. Eur. J. Clin. Nutr. 2016, 70, 155–161. [CrossRef] [PubMed]
134. Shapiro, H.; Theilla, M.; Attal-Singer, J.; Singer, P. Effects of polyunsaturated fatty acid consumption in diabetic nephropathy. Nat. Rev. Nephrol. 2011, 7, 110–121. [CrossRef] [PubMed]
135. Fassett, R.G.; Gobe, G.C.; Peake, J.M.; Coombes, J.S. Omega-3 Polyunsaturated Fatty Acids in the Treatment of Kidney Disease. Am. J. Kidney Dis. 2010, 56, 728–742. [CrossRef] [PubMed]
136. Christensen, J.H.; Schmidt, E.B.; Svensson, M. n-3 polyunsaturated fatty acids, lipids and lipoproteins in end-stage renal disease. Clin. Lipidol. 2011, 6, 563–576. [CrossRef]
137. Eslick, G.D.; Howe, P.R.C.; Smith, C.; Priest, R.; Bensoussan, A. Benefits of fish oil supplementation in hyperlipidemia: A systematic review and meta-analysis. Int. J. Cardiol. 2009, 136, 4–16. [CrossRef] [PubMed]
138. Mori, T.A.; Burke, V.; Puddey, I.; Irish, A.; Cowpland, C.A.; Beilin, L.; Dogra, G.; Watts, G.F. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: A randomized controlled trial. J. Hypertens. 2009, 27, 1863–1872. [CrossRef] [PubMed]
139. Svensson, M.; Christensen, J.H.; Sølling, J.; Schmidt, E.B. The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. Am. J. Kidney Dis. 2004, 44, 77–83. [CrossRef] [PubMed]
140. Guebre-Egziabher, F.; Debard, C.; Drai, J.; Denis, L.; Pesenti, S.; Bienvenu, J.; Vidal, H.; Laville, M.; Fouque, D. Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients. Nutrition 2013, 29, 730–736. [CrossRef] [PubMed]
141. Svensson, M.; Schmidt, E.B.; Jørgensen, K.A.; Christensen, J.H. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: A randomized placebo-controlled intervention study. Nephrol. Dial. Transplant. 2008, 23, 2918–2924. [CrossRef] [PubMed]
142. Khajehdehi, P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J. Ren. Nutr. 2000, 10, 191–195. [CrossRef] [PubMed]
143. Ando, M.; Sanaka, T.; Nihei, H. Eicosapentanoic Acid Reduces Plasma Levels of Remnant Lipoproteins and Prevents in Vivo Peroxidation of LDL in Dialysis Patients. J. Am. Soc. Nephrol. 1999, 10, 2177–2184. [PubMed]
144. Kooshki, A.; Taleban, F.A.; Tabibi, H.; Hedayati, M. Effects of Omega-3 Fatty Acids on Serum Lipids, Lipoprotein (a), and Hematologic Factors in Hemodialysis Patients. Ren. Fail. 2011, 33, 892–898. [CrossRef] [PubMed]
145. Saifullah, A.; Watkins, B.A.; Saha, C.; Li, Y.; Moe, S.M.; Friedman, A.N. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients—A pilot study. Nephrol. Dial. Transplant. 2007, 22, 3561–3567. [CrossRef] [PubMed]
146. Perunicic-Pekovic, G.B.; Rasic, Z.R.; Pljesa, S.I.; Sobajic, S.S.; Djuricic, I.; Maletic, R.; Ristic-Medic, D.K. Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology 2007, 12, 331–336. [CrossRef] [PubMed]
147. Taziki, O.; Lessan-Pezeshki, M.; Akha, O.; Vasheghani, F. The Effect of Low Dose Omega-3 on Plasma Lipids in Hemodialysis Patients. Saudi J. Kidney Dis. Transpl. 2007, 18, 571. [PubMed]
148. Poulia, K.-A.; Panagiotakos, D.B.; Tourlede, E.; Rezou, A.; Stamatiadis, D.; Boletis, J.; Zampelas, A. Omega-3 Fatty Acids Supplementation Does Not Affect Serum Lipids in Chronic Hemodialysis Patients. J. Ren. Nutr. 2011, 21, 479–484. [CrossRef] [PubMed]
149. Donnelly, S.M.; Ali, M.A.; Churchill, D.N. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. J. Am. Soc. Nephrol. 1992, 2, 1634–1639. [PubMed]
150. Schmitz, P.G.; McCloud, L.K.; Reikes, S.T.; Leonard, C.L.; Gellens, M.E. Prophylaxis of Hemodialysis Graft Thrombosis with Fish Oil: Double-Blind, Randomized, Prospective Trial. J. Am. Soc. Nephrol. 2002, 13, 184–190. [PubMed]
151. Bowden, R.G.; Jitomir, J.; Wilson, R.L.; Gentile, M. Effects of Omega-3 Fatty Acid Supplementation on Lipid Levels in Endstage Renal Disease Patients. J. Ren. Nutr. 2009, 19, 259–266. [CrossRef] [PubMed]
152. Tayebi-Khosroshahi, H.; Dehgan, R.; Habibi Asl, B.; Safaian, A.; Panahi, F.; Estakhri, R.; Purasgar, B. Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients. Iran J. Kidney Dis. 2013, 7, 479–484. [PubMed]
153. Rasic-Milutinovic, Z.; Perunicic, G.; Pljesa, S.; Gluvic, Z.; Sobajic, S.; Djuric, I.; Ristic, D. Effects of N-3 PUFAs Supplementation on Insulin Resistance and Inflammatory Biomarkers in Hemodialysis Patients. Ren. Fail. 2007, 29, 321–329. [CrossRef] [PubMed]
154. An, W.S.; Lee, S.M.; Son, Y.K.; Kim, S.E.; Kim, K.H.; Han, J.Y.; Bae, H.R.; Rha, S.H.; Park, Y. Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients. Nutr. Res. 2012, 32, 495–502. [CrossRef] [PubMed]
155. Bowden, R.G.; Wilson, R.L.; Deike, E.; Gentile, M. Fish Oil Supplementation Lowers C-Reactive Protein Levels Independent of Triglyceride Reduction in Patients With End-Stage Renal Disease. Nutr. Clin. Pract. 2009, 24, 508–512. [CrossRef] [PubMed]
156. Lok, C.E.; Moist, L.; Hemmelgarn, B.R.; Tonelli, M.; Vazquez, M.A.; Dorval, M.; Oliver, M.; Donnelly, S.; Allon, M.; Stanley, K. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: A randomized trial. JAMA 2012, 307, 1809–1816. [CrossRef] [PubMed]
157. Bessell, E.; Jose, M.D.; McKercher, C. Associations of fish oil and vitamin B and E supplementation with cardiovascular outcomes and mortality in people receiving haemodialysis: A review. BMC Nephrol. 2015, 16, 1–8. [CrossRef] [PubMed]
158. Zhu, W.; Dong, C.; Du, H.; Zhang, H.; Chen, J.; Hu, X.; Hu, F. Effects of fish oil on serum lipid profile in dialysis patients: A systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2014, 13, 127. [CrossRef] [PubMed]
159. Schuchardt, J.P.; Hahn, A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot. Essent. Fat. Acids 2013, 89, 1–8. [CrossRef] [PubMed]
160. Khawaja, O.A.; Gaziano, J.M.; Djoussé, L. N-3 Fatty Acids for Prevention of Cardiovascular Disease. Curr. Atheroscler. Rep. 2014, 16, 1–7. [CrossRef] [PubMed]
161. Chi, H.; Lin, X.; Huang, H.; Zheng, X.; Li, T.; Zou, Y. Omega-3 Fatty Acid Supplementation on Lipid Profiles in Dialysis Patients: Meta-analysis. Arch. Med. Res. 2014, 45, 469–477. [CrossRef] [PubMed]
162. He, L.; Li, M.-S.; Lin, M.; Zhao, T.-Y.; Gao, P. Effect of fish oil supplement in maintenance hemodialysis patients: A systematic review and meta-analysis of published randomized controlled trials. Eur. J. Clin. Pharmacol. 2016, 72, 129–139. [CrossRef] [PubMed]
163. Singh, S. Hypertension in chronic kidney disease. Clin. Queries Nephrol. 2013, 2, 15–22. [CrossRef]
164. Miller, E.R.; Juraschek, S.P.; Anderson, C.A.; Guallar, E.; Henoch-Ryugo, K.; Charleston, J.; Turban, S.; Bennett, M.R.; Appel, L.J. The Effects of n-3 Long-Chain Polyunsaturated Fatty Acid Supplementation on Biomarkers of Kidney Injury in Adults with Diabetes: Results of the GO-FISH trial. Diabetes Care 2013, 36, 1462–1469. [CrossRef] [PubMed]
165. Miller, P.E.; Van Elswyk, M.; Alexander, D.D. Long-Chain Omega-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid and Blood Pressure: A Meta-Analysis of Randomized Controlled Trials. Am. J. Hypertens. 2014, 27, 885–896. [CrossRef] [PubMed]
166. Friedman, A.N. Omega-3 Fatty Acid Supplementation in Advanced Kidney Disease. Semin. Dial. 2010, 23, 396–400. [CrossRef] [PubMed]
167. Friedman, A.; Moe, S. Review of the Effects of Omega-3 Supplementation in Dialysis Patients. Clin. J. Am. Soc. Nephrol. 2006, 1, 182–192. [CrossRef] [PubMed]
168. Noori, N.; Dukkipati, R.; Kovesdy, C.P.; Sim, J.J.; Feroze, U.; Murali, S.B.; Bross, R.; Benner, D.; Kopple, J.D.; Kalantar-Zadeh, K. Dietary Omega-3 Fatty Acid, Ratio of Omega-6 to Omega-3 Intake, Inflammation, and Survival in Long-term Hemodialysis Patients. Am. J. Kidney Dis. 2011, 58, 248–256. [CrossRef] [PubMed]
169. An, W.S.; Lee, S.M.; Son, Y.K.; Kim, S.E.; Kim, K.H.; Han, J.Y.; Bae, H.R.; Park, Y. Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukot. Essent. Fat. Acids 2012, 86, 29–34. [CrossRef] [PubMed]
170. Gharekhani, A.; Khatami, M.-R.; Dashti-khavidaki, S.; Razeghi, E.; Noorbala, A.-A.; Hashemi-nazari, S.-S.; Mansournia, M.-A. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: A randomized, placebo-controlled clinical trial. Eur. J. Clin. Pharmacol. 2014, 70, 655–665. [CrossRef] [PubMed]
171. Hung, A.M.; Booker, C.; Ellis, C.D.; Siew, E.D.; Graves, A.J.; Shintani, A.; Abumrad, N.N.; Himmelfarb, J.; Ikizler, T.A. Omega-3 fatty acids inhibit the up-regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrol. Dial. Transplant. 2015, 30, 266–274. [CrossRef] [PubMed]
172. Bazeley, J.; Bieber, B.; Li, Y.; Morgenstern, H.; de Sequera, P.; Combe, C.; Yamamoto, H.; Gallagher, M.; Port, F.K.; Robinson, B.M. C-Reactive Protein and Prediction of 1-Year Mortality in Prevalent Hemodialysis Patients. Clin. J. Am. Soc. Nephrol. 2011, 6, 2452–2461. [CrossRef] [PubMed]
173. Liu, S.-H.; Li, Y.-J.; Wu, H.-H.; Lee, C.-C.; Lin, C.-Y.; Weng, C.-H.; Chen, Y.-C.; Chang, M.-Y.; Hsu, H.-H.; Fang, J.-T.; et al. High-Sensitivity C-Reactive Protein Predicts Mortality and Technique Failure in Peritoneal Dialysis Patients. PLoS ONE 2014, 9, e93063. [CrossRef] [PubMed]
174. Möllsten, A.V.; Dahlquist, G.G.; Stattin, E.-L.; Rudberg, S. Higher Intakes of Fish Protein Are Related to a Lower Risk of Microalbuminuria in Young Swedish Type 1 Diabetic Patients. Diabetes Care 2001, 24, 805–810. [CrossRef] [PubMed]
175. Miller, E.R.; Juraschek, S.P.; Appel, L.J.; Madala, M.; Anderson, C.A.; Bleys, J.; Guallar, E. The effect of n–3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: Meta-analysis of clinical trials. Am. J. Clin. Nutr. 2009, 89, 1937–1945. [CrossRef] [PubMed]
176. Chou, H.H.; Chiou, Y.Y.; Hung, P.H.; Chiang, P.C.; Wang, S.T. Omega-3 Fatty Acids Ameliorate Proteinuria but Not Renal Function in IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Nephron Clin. Pract. 2012, 121, c30–c35. [CrossRef] [PubMed]
177. Lee, S.M.; Chung, S.H.; Park, Y.; Park, M.K.; Son, Y.K.; Kim, S.E.; An, W.S. Effect of Omega-3 Fatty Acid on the Fatty Acid Content of the Erythrocyte Membrane and Proteinuria in Patients with Diabetic Nephropathy. Int. J. Endocrinol. 2015, 2015, 8. [CrossRef] [PubMed]
178. Shimizu, H.; Ohtani, K.-I.; Tanaka, Y.; Sato, N.; Mori, M.; Shimomura, Y. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes Res. Clin. Pract. 1995, 28, 35–40. [CrossRef]
179. Madsen, T.; Christensen, J.H.; Svensson, M.; Witt, P.M.; Toft, E.; Schmidt, E.B. Marine n-3 polyunsaturated fatty acids in patients with end-stage renal failure and in subjects without kidney disease: A comparative study. J. Ren. Nutr. 2011, 21, 169–175. [CrossRef] [PubMed]
180. Friedman, A.N.; Saha, C.; Watkins, B.A. A Feasbility Study of Erythrocyte Long Chain Omega-3 Polyunsaturated Fatty Acid Content and Mortality Risk in Hemodialysis Patients. J. Ren. Nutr. 2008, 18, 509–512. [CrossRef] [PubMed]
181. Terashima, Y.; Hamazaki, K.; Itomura, M.; Tomita, S.; Kuroda, M.; Hirata, H.; Hamazaki, T.; Inadera, H. Inverse association between docosahexaenoic acid and mortality in patients on hemodialysis during over 10 years. Hemodial. Int. 2014, 18, 625–631. [CrossRef] [PubMed]
182. Hamazaki, K.; Terashima, Y.; Itomura, M.; Sawazaki, S.; Inagaki, H.; Kuroda, M.; Tomita, S.; Hirata, H.; Inadera, H.; Hamazaki, T. Docosahexaenoic Acid Is an Independent Predictor of All-Cause Mortality in Hemodialysis Patients. Am. J. Nephrol. 2011, 33, 105–110. [CrossRef] [PubMed]
183. Friedman, A.N.; Yu, Z.; Tabbey, R.; Denski, C.; Tamez, H.; Wenger, J.; Thadhani, R.; Li, Y.; Watkins, B.A. Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney Int. 2013, 83, 1130–1135. [CrossRef] [PubMed]
184. Shoji, T.; Kakiya, R.; Hayashi, T.; Tsujimoto, Y.; Sonoda, M.; Shima, H.; Mori, K.; Fukumoto, S.; Tahara, H.; Shioi, A.; et al. Serum n-3 and n-6 Polyunsaturated Fatty Acid Profile as an Independent Predictor of Cardiovascular Events in Hemodialysis Patients. Am. J. Kidney Dis. 2013, 62, 568–576. [CrossRef] [PubMed]
185. Metcalf, R.G.; James, M.J.; Gibson, R.A.; Edwards, J.R.; Stubberfield, J.; Stuklis, R.; Roberts-Thomson, K.; Young, G.D.; Cleland, L.G. Effects of fish-oil supplementation on myocardial fatty acids in humans. Am. J. Clin. Nutr. 2007, 85, 1222–1228. [PubMed]
186. Kutner, N.G.; Clow, P.W.; Zhang, R.; Aviles, X. Association of fish intake and survival in a cohort of incident dialysis patients. Am. J. Kidney Dis. 2002, 39, 1018–1024. [CrossRef] [PubMed]
187. Inoue, T.; Okano, K.; Tsuruta, Y.; Tsuruta, Y.; Tsuchiya, K.; Akiba, T.; Nitta, K. Eicosapentaenoic Acid (EPA) Decreases the All-Cause Mortality in Hemodialysis Patients. Intern. Med. 2015, 54, 3133–3137. [CrossRef] [PubMed]
188. Svensson, M.; Schmidt, E.B.; Jørgensen, K.A.; Christensen, J.H.; Group obotOS. N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: A Randomized, Placebo-Controlled Intervention Trial. Clin. J. Am. Soc. Nephrol. 2006, 1, 780–786. [CrossRef] [PubMed]
189. Zabel, R.; Ash, S.; King, N.; Bauer, J. Adherence to Fish Oil Intervention in Patients with Chronic Kidney Disease. J. Ren. Nutr. 2010, 20, 329–333. [CrossRef] [PubMed]
190. Chowdhury, R.; Stevens, S.; Gorman, D.; Pan, A.; Warnakula, S.; Chowdhury, S.; Ward, H.; Johnson, L.; Crowe, F.; Hu, F.B.; et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: Systematic review and meta-analysis. BMJ 2012, 345, e6698. [CrossRef] [PubMed]
191. Visioli, F.; Risé, P.; Barassi, M.C.; Marangoni, F.; Galli, C. Dietary intake of fish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids 2003, 38, 415–418. [CrossRef] [PubMed]
192. Bernstein, A.M.; Pan, A.; Rexrode, K.M.; Stampfer, M.; Hu, F.B.; Mozaffarian, D.; Willett, W.C. Dietary Protein Sources and the Risk of Stroke in Men and Women. Stroke 2012, 43, 637. [CrossRef] [PubMed]
193. Johnson, R.J.; Sanchez-Lozada, L.G.; Nakagawa, T. The effect of fructose on renal biology and disease. J. Am. Soc. Nephrol. 2010, 21, 2036–2039. [CrossRef] [PubMed]
194. Singh AKab, Kari JAc: Metabolic syndrome and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2013, 22, 198–203.
195. Bomback, A.S.; Derebail, V.K.; Shoham, D.A.; Anderson, C.A.; Steffen, L.M.; Rosamond, W.D.; Kshirsagar, A.V. Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int. 2010, 77, 609–616. [CrossRef] [PubMed]
196. Nakayama, T.; Kosugi, T.; Gersch, M.; Connor, T.; Sanchez-Lozada, L.G.; Lanaspa, M.A.; Roncal, C.; Perez-Pozo, S.E.; Johnson, R.J.; Nakagawa, T. Dietary fructose causes tubulointerstitial injury in the normal rat kidney. Am. J. Physiol. Ren. Physiol. 2010, 298, F712–F720. [CrossRef] [PubMed]
197. Cirillo, P.; Gersch, M.S.; Mu, W.; Scherer, P.M.; Kim, K.M.; Gesualdo, L.; Henderson, G.N.; Johnson, R.J.; Sautin, Y.Y. Ketohexokinase-Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular Cells. J. Am. Soc. Nephrol. 2009, 20, 545–553. [CrossRef] [PubMed]
198. Shoham, D.A.; Durazo-Arvizu, R.; Kramer, H.; Luke, A.; Vupputuri, S.; Kshirsagar, A.; Cooper, R.S. Sugary soda consumption and albuminuria: Results from the National Health and Nutrition Examination Survey, 1999–2004. PLoS ONE 2008, 3, e3431. [CrossRef] [PubMed]
199. Choi, J.W.J.; Ford, E.S.; Gao, X.; Choi, H.K. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The third national health and nutrition examination survey. Arthritis Care Res. 2008, 59, 109–116. [CrossRef] [PubMed]
200. Gao, X.; Qi, L.; Qiao, N.; Choi, H.K.; Curhan, G.; Tucker, K.L.; Ascherio, A. Intake of Added Sugar and Sugar-Sweetened Drink and Serum Uric Acid Concentration in US Men and Women. Hypertension 2007, 50, 306–312. [CrossRef] [PubMed]
201. Saldana, T.M.; Basso, O.; Darden, R.; Sandler, D.P. Carbonated beverages and chronic kidney disease. Epidemiology 2007, 18, 501. [CrossRef] [PubMed]
202. Yuzbashian, E.; Asghari, G.; Mirmiran, P.; Zadeh-Vakili, A.; Azizi, F. Sugar-sweetened beverage consumption and risk of incident chronic kidney disease: Tehran Lipid and Glucose Study. Nephrology 2016, 21, 608–616. [CrossRef] [PubMed]
203. Lin, J.; Curhan, G.C. Associations of Sugar and Artificially Sweetened Soda with Albuminuria and Kidney Function Decline in Women. Clin. J. Am. Soc. Nephrol. 2011, 6, 160–166. [CrossRef] [PubMed]
204. Cheungpasitporn, W.; Thongprayoon, C.; O’Corragain, O.A.; Edmonds, P.J.; Kittanamongkolchai, W.; Erickson, S.B. Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: A systematic review and meta-analysis. Nephrology 2014, 19, 791–797. [CrossRef] [PubMed]
205. Karalius, V.P.; Shoham, D.A. Dietary sugar and artificial sweetener intake and chronic kidney disease: A review. Adv. Chronic Kidney Dis. 2013, 20, 157–164. [CrossRef] [PubMed]
206. Gersch, M.S.; Mu, W.; Cirillo, P.; Reungjui, S.; Zhang, L.; Roncal, C.; Sautin, Y.Y.; Johnson, R.J.; Nakagawa, T. Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am. J. Physiol. Ren. Physiol. 2007, 293, F1256–F1261. [CrossRef] [PubMed]
207. Tapia, E.; Cristóbal, M.; García-Arroyo, F.E.; Soto, V.; Monroy-Sánchez, F.; Pacheco, U.; Lanaspa, M.A.; Roncal-Jiménez, C.A.; Cruz-Robles, D.; Ishimoto, T.; et al. Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats. Am. J. Physiol. Ren. Physiol. 2013, 304, F727–F736. [CrossRef] [PubMed]
208. Wang, D.D.; Sievenpiper, J.L.; de Souza, R.J.; Chiavaroli, L.; Ha, V.; Cozma, A.I.; Mirrahimi, A.; Matthew, E.Y.; Carleton, A.J.; Di Buono, M. The effects of fructose intake on serum uric acid vary among controlled dietary trials. J. Nutr. 2012, 142, 916–923. [CrossRef] [PubMed]
209. Brymora, A.; Flisiński, M.; Johnson, R.J.; Goszka, G.; Stefańska, A.; Manitius, J. Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2012, 27, 608–612. [CrossRef] [PubMed]
210. Poulsen, M.W.; Hedegaard, R.V.; Andersen, J.M.; de Courten, B.; Bügel, S.; Nielsen, J.; Skibsted, L.H.; Dragsted, L.O. Advanced glycation endproducts in food and their effects on health. Food Chem. Toxicol. 2013, 60, 10–37. [CrossRef] [PubMed]
211. Penfold, S.A.; Coughlan, M.T.; Patel, S.K.; Srivastava, P.M.; Sourris, K.C.; Steer, D.; Webster, D.E.; Thomas, M.C.; MacIsaac, R.J.; Jerums, G.; et al. Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int. 2010, 78, 287–295. [CrossRef] [PubMed]
212. Kratochvilová, M.; Zakiyanov, O.; Kalousová, M.; Kříha, V.; Zima, T.; Tesař, V. Associations of Serum Levels of Advanced Glycation end Products with Nutrition Markers and Anemia in Patients with Chronic Kidney Disease. Ren. Fail. 2011, 33, 131–137. [CrossRef] [PubMed]
213. Nakamura, T.; Sato, E.; Fujiwara, N.; Kawagoe, Y.; Ueda, Y.; Suzuki, T.; Yamada, S.; Takeuchi, M.; Fukami, K.; Ueda, S. Positive association of serum levels of advanced glycation end products and high mobility group box–1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 2009, 58, 1624–1628. [CrossRef] [PubMed]
214. Henle, T.; Miyata, T. Advanced glycation end products in uremia. Adv. Ren. Replace. Ther. 2003, 10, 321–331. [CrossRef] [PubMed]
215. Koschinsky, T.; He, C.-J.; Mitsuhashi, T.; Bucala, R.; Liu, C.; Buenting, C.; Heitmann, K.; Vlassara, H. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. USA 1997, 94, 6474–6479. [CrossRef] [PubMed]
216. Uribarri, J.; Peppa, M.; Cai, W.; Goldberg, T.; Lu, M.; Baliga, S.; Vassalotti, J.A.; Vlassara, H. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am. J. Kidney Dis. 2003, 42, 532–538. [CrossRef]
217. Semba, R.D.; Fink, J.C.; Sun, K.; Windham, B.G.; Ferrucci, L. Serum Carboxymethyl-lysine, a Dominant Advanced Glycation End Product, is Associated with Chronic Kidney Disease: The Baltimore Longitudinal Study of Aging. J. Ren. Nutr. 2010, 20, 74–81. [CrossRef] [PubMed]
218. D’Agati, V.; Schmidt, A.M. RAGE and the pathogenesis of chronic kidney disease. Nat. Rev. Nephrol. 2010, 6, 352–360. [CrossRef] [PubMed]
219. Goldin, A.; Beckman, J.A.; Schmidt, A.M.; Creager, M.A. Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 2006, 114, 597–605. [CrossRef] [PubMed]
220. Ott, C.; Jacobs, K.; Haucke, E.; Navarrete Santos, A.; Grune, T.; Simm, A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014, 2, 411–429. [CrossRef] [PubMed]
221. Scivittaro, V.; Ganz, M.B.; Weiss, M.F. AGEs induce oxidative stress and activate protein kinase C-βII in neonatal mesangial cells. Am. J. Physiol. Ren. Physiol. 2000, 278, F676–F683.
222. Li, J.; Schmidt, A.M. Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products. J. Biol. Chem. 1997, 272, 16498–16506. [CrossRef] [PubMed]
223. Coughlan, M.T.; Thorburn, D.R.; Penfold, S.A.; Laskowski, A.; Harcourt, B.E.; Sourris, K.C.; Tan, A.L.; Fukami, K.; Thallas-Bonke, V.; Nawroth, P.P.; et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 2009, 20, 742–752. [CrossRef] [PubMed]
224. Hou, F.F.; Ren, H.; Owen, W.F.; Guo, Z.J.; Chen, P.Y.; Schmidt, A.M.; Miyata, T.; Zhang, X. Enhanced Expression of Receptor for Advanced Glycation End Products in Chronic Kidney Disease. J. Am. Soc. Nephrol. 2004, 15, 1889–1896. [CrossRef] [PubMed]
225. Busch, M.; Franke, S.; Muller, A.; Wolf, M.; Gerth, J.; Ott, U.; Niwa, T.; Stein, G. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int. 2004, 66, 338–347. [CrossRef] [PubMed]
226. Busch, M.; Franke, S.; Wolf, G.; Brandstädt, A.; Ott, U.; Gerth, J.; Hunsicker, L.G.; Stein, G. The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension. Am. J. Kidney Dis. 2006, 48, 571–579. [CrossRef] [PubMed]
227. Schwedler, S.B.; Metzger, T.; Schinzel, R.; Wanner, C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 2002, 62, 301–310. [CrossRef] [PubMed]
228. Stein, G.; Busch, M.; Muller, A.; Wendt, T.; Franke, C.; Niwa, T.; Franke, S. Are advanced glycation end products cardiovascular risk factors in patients with CRF? Am. J. Kidney Dis. 2003, 41, S52–S56. [CrossRef] [PubMed]
229. Suliman, M.E.; Heimburger, O.; Barany, P.; Anderstam, B.; Pecoits-Filho, R.; Rodriguez Ayala, E.; Qureshi, A.R.; Fehrman-Ekholm, I.; Lindholm, B.; Stenvinkel, P. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J. Am. Soc. Nephrol. 2003, 14, 1614–1622. [CrossRef] [PubMed]
230. Wagner, Z.; Molnár, M.; Molnár, G.A.; Tamaskó, M.; Laczy, B.; Wagner, L.; Csiky, B.; Heidland, A.; Nagy, J.; Wittmann, I. Serum Carboxymethyllysine Predicts Mortality in Hemodialysis Patients. Am. J. Kidney Dis. 2006, 47, 294–300. [CrossRef] [PubMed]
231. Meerwaldt, R.; Hartog, J.W.L.; Graaff, R.; Huisman, R.J.; Links, T.P.; den Hollander, N.C.; Thorpe, S.R.; Baynes, J.W.; Navis, G.; Gans, R.O.B.; et al. Skin Autofluorescence, a Measure of Cumulative Metabolic Stress and Advanced Glycation End Products, Predicts Mortality in Hemodialysis Patients. J. Am. Soc. Nephrol. 2005, 16, 3687–3693. [CrossRef] [PubMed]
232. Feng, J.X.; Hou, F.F.; Liang, M.; Wang, G.B.; Zhang, X.; Li, H.Y.; Xie, D.; Tian, J.W.; Liu, Z.Q. Restricted intake of dietary advanced glycation end products retards renal progression in the remnant kidney model. Kidney Int. 2007, 71, 901–911. [CrossRef] [PubMed]
233. Šebeková, K.; Faist, V.; Hofmann, T.; Schinzel, R.; Heidland, A. Effects of a diet rich in advanced glycation end products in the rat remnant kidney model. Am. J. Kidney Dis. 2003, 41, S48–S51. [CrossRef] [PubMed]
234. ŠEbeková, K.; Hofmann, T.; Boor, P.; ŠEbeková, K.; Ulicná, O.G.; Erbersdobler, H.F.; Baynes, J.W.; Thorpe, S.R.; Heidland, A.; Somoza, V. Renal Effects of Oral Maillard Reaction Product Load in the Form of Bread Crusts in Healthy and Subtotally Nephrectomized Rats. Ann. N. Y. Acad. Sci. 2005, 1043, 482–491. [CrossRef] [PubMed]
235. Zheng, F.; He, C.; Cai, W.; Hattori, M.; Steffes, M.; Vlassara, H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab. Res. Rev. 2002, 18, 224–237. [CrossRef] [PubMed]
236. Somoza, V.; Lindenmeier, M.; Hofmann, T.; Frank, O.; Erbersdobler, H.F.; Baynes, J.W.; Thorpe, S.R.; Heidland, A.; Zill, H.; Bek, S.; et al. Dietary bread crust advanced glycation end products bind to the receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral administration to healthy and subtotally nephrectomized rats. Ann. N. Y. Acad. Sci. 2005, 1043, 492–500. [CrossRef] [PubMed]
237. Tan, A.L.Y.; Sourris, K.C.; Harcourt, B.E.; Thallas-Bonke, V.; Penfold, S.; Andrikopoulos, S.; Thomas, M.C.; O’Brien, R.C.; Bierhaus, A.; Cooper, M.E.; et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am. J. Physiol.-Ren. Physiol. 2010, 298, F763–F770. [CrossRef] [PubMed]
238. Uribarri, J.; Peppa, M.; Cai, W.; Goldberg, T.; Lu, M.; He, C.; Vlassara, H. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. Int. J. Am. Soc. Nephrol. 2003, 14, 728–731. [CrossRef]
239. Vlassara, H.; Cai, W.; Goodman, S.; Pyzik, R.; Yong, A.; Chen, X.; Zhu, L.; Neade, T.; Beeri, M.; Silverman, J.M.; et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the antiinflammatory age receptor-1. J. Clin. Endocrinol. Metab. 2009, 94, 4483–4491. [CrossRef] [PubMed]
240. Harcourt, B.E.; Sourris, K.C.; Coughlan, M.T.; Walker, K.Z.; Dougherty, S.L.; Andrikopoulos, S.; Morley, A.L.; Thallas-Bonke, V.; Chand, V.; Penfold, S.A.; et al. Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int. 2011, 80, 190–198. [CrossRef] [PubMed]